Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 14/20 | 0.59 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6561693 | 0.87 | GRIA4 (0.55) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6563303 | 0.84 | GRIA4 (0.80) | GRIA4GRIA2GRIA1GRIA3ALDH1A1 | |
| SCHEMBL6563108 | 0.81 | CA1 (0.50) | GRIA4GRIA2L3MBTL1 | |
| SCHEMBL5877913 | 0.80 | GRIA4 (0.87) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6565191 | 0.80 | GRIA4 (0.50) | GRIA4ALDH1A1L3MBTL1NPSR1 | |
| SCHEMBL2608935 | 0.79 | GRIA4 (0.52) | GRIA4 | |
| SCHEMBL7166935 | 0.78 | GRIA4 (0.66) | GRIA4ALDH1A1L3MBTL1 | |
| SCHEMBL338391 | 0.78 | GRIA4 (0.81) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL3704221 | 0.78 | GRIA4 (0.81) | GRIA4GRIA2GRIA1GRIA3 | |
| SCHEMBL6554405 | 0.78 | GRIA4 (0.81) | GRIA4GRIA2GRIA1GRIA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | GRIA4 17/4885GRIA2 8/4885GRIA1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.